Allergan Drops Patent, Ad Claims Over Eyelash Drug Latisse

Law360, New York (March 29, 2013, 2:03 PM EDT) -- A California federal judge Thursday brought closer to an end Allergan Inc.’s long-running patent infringement and false advertising suit over its eyelash-enhancing drug Latisse after the company inked a deal that dropped competition and noninfringement claims by three rivals.

U.S. District Judge James V. Selna agreed to dismiss Allergan’s infringement and false ad claims as well as attempted monopolization and unfair competition counterclaims from Athena Cosmetics Inc. and noninfringement counterclaims from Athena, Pharma Tech International Inc. and Northwest Cosmetic Laboratories LLC after the parties said they’d...
To view the full article, register now.